Skin-Infection Outcomes in 3,371 Naval Special Warfare Trainees

November 12, 2026

Doctor’s Notes · Life in Motion · Evidence Review

Editorial disclosure: The featured image is an AI-created illustration of a fictional activity or service setting. It is not a patient, diagnosis, before-and-after image, institutional endorsement or Dr. Arsy #003 treatment result.

Reader question: What did this specific study measure, in whom, at what timepoint—and which conclusions would go beyond its evidence?

Study snapshot

Study element	Reported detail
Population	3,371 Naval Special Warfare trainees: 1,024 before and 2,347 after a prophylaxis-policy change.
Design	Retrospective before-and-after cohort evaluating skin and soft-tissue infection and hospital admission after doxycycline prophylaxis.
Comparator	Trainees before the policy were compared with trainees after implementation.
Timepoint	Training episodes covered by the pre-policy and post-policy periods.
Key result	There were 284 infections and 29 admissions. Admissions fell from 1.37 to 0.64 per 100 trainees (rate ratio 0.468, 95% CI 0.226–0.968; p=0.036), while overall infection rates of 7.42 versus 8.86 per 100 were not significantly different (p=0.185). Admissions per infection fell from 18.4% to 7.2% (p=0.0089); mean stay fell from 9.07 to 4.33 days.
Funding/conflict context	The study evaluated an antibiotic policy, not a moisturizer. Its drug outcomes cannot be transferred to Dr. Arsy #003. The accessible abstract does not state commercial cosmetic funding.

What was actually measured?

There were 284 infections and 29 admissions. Admissions fell from 1.37 to 0.64 per 100 trainees (rate ratio 0.468, 95% CI 0.226–0.968; p=0.036), while overall infection rates of 7.42 versus 8.86 per 100 were not significantly different (p=0.185). Admissions per infection fell from 18.4% to 7.2% (p=0.0089); mean stay fell from 9.07 to 4.33 days.

The admission outcomes changed while total infection incidence did not, so the result is about severity and utilization under a drug policy—not cosmetic prevention.

The denominator defines the scope. A clinic series, outbreak investigation, surveillance database, questionnaire and prospective cohort answer different questions. Their percentages, rates and associations cannot be silently transferred to a different population, activity or setting.

What the result does not prove

Nonrandomized before-and-after design, changing cohorts and clinical practice, possible diagnostic differences and antibiotic-specific risks limit causal and external inference.

Observational timing and association do not automatically prove individual causation. Training load, footwear, shared surfaces, hygiene, climate, protective equipment, prior conditions, referral practices and access to care may all change an estimate.

A PubMed record is a bibliographic source. PubMed indexing is not NIH endorsement of the authors’ conclusions, this interpretation or any product.

Drug-study boundary: This study evaluated doxycycline prophylaxis. Its antibiotic outcomes, adverse-effect profile and clinical decisions cannot be transferred to a cosmetic moisturizer or used as a claim for Dr. Arsy #003.

Condition categories should stay separate

Dryness, friction injury, dermatitis, fungal disease and bacterial infection are not interchangeable. A moisturizer may support hydration and the moisture barrier, but it does not diagnose an infection, replace medical evaluation or substitute for activity-specific prevention and infection-control measures.

For suspected infection, clinicians may need examination, microscopy, culture or other testing. Persistent spreading redness, drainage, fever, severe pain, rapidly worsening symptoms or major loss of function warrants prompt professional evaluation.

Activity details worth documenting

Which surface, footwear, glove, mat, pool, uniform, climate or training load came before the change?
Where did the problem begin, and did it change during rest, travel, deployment or a different facility?
Were skin, towels, clothing, equipment or showers shared, and how were surfaces cleaned?
How often were skin areas wet, occluded, rubbed, heated, chilled or exposed to sun?
Did the problem alter sleep, pace, attendance, training, competition or work safety?

Prevention comes before cosmetic care

Useful prevention is matched to the hazard: equipment and facility hygiene, prompt showering, clean personal textiles, well-fitted footwear, friction management, task-appropriate protective equipment, ultraviolet protection and timely clinical assessment. No single step prevents every diagnosis.

Do not share personal skin products during an outbreak and do not place workplace or environmental materials on skin to test a theory. Follow facility, occupational-health, sports-medicine and public-health instructions for contagious conditions.

Primary research and authoritative guidance

Where Dr. Arsy #003 fits

Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003. Its findings do not show that #003 treats, cures or prevents eczema or infection, relieves pain or itch, neutralizes environmental exposures, is appropriate for every person, or provides pediatric or 24-hour efficacy.

Continue the evidence series

Evidence note: This educational article separates reported findings from interpretation. It is not a diagnosis, treatment recommendation or workplace, military, sports or infection-control determination.

← Back to Doctor's Notes